Cough, particularly at night, is a major symptom of asthma. Although wheeze is a hallmark of asthma, cough may be the more prominent symptom. The relationship of cough and wheeze in asthma and the underlying mechanisms involved have not been fully elucidated. 1 Night cough in asthma may reflect diurnal variation in peak flow2 but the timing of coughing episodes3 does not necessarily coincide with that of minimum peak flow. Another possible explanation for increased symptoms at night is that daytime medication with short acting inhaled bronchodilators is insufficient to control night time symptoms. Oral controlled release salbutamol has been marketed as having a place in control of night time asthma. Twice daily dosage of 4 or 8 mg tablets provides a smooth plasma profile4 and comparison of controlled release salbutamol (CRS) with oral theophyllines has shown the preparations to be equally effective in adult asthma.5 6 Preliminary results in children gave similar results.7 These studies have also shown that CRS is well tolerated with fewer adverse effects.
The aim of this study was to ascertain the effectiveness of CRS in asthmatic children with persistent night cough.
Subjects
Twenty seven children aged 6-14 years with moderate to severe asthma who attended the children's chest clinic at Leicester Royal Infirmary on a regular basis were considered initially for enrolment into the study. The diagnosis of asthma was made on the basis of clincal findings and the demonstration ofreversible airway obstructio'n (>15% increase in peak flow after inhalation ofsalbutamol). The children were considered for the study if, in addition, there was a history of persistent night cough (of several months' duration) not controlled by current medication or associated with a recent upper respiratory ipfection. Although cough is a common feature of asthma, persistent cough was uncommon in patients attending the clinic and recruitment took a period of two years. Children already receiving theophylline preparations, long acting P2 agonists, or oral steroids were excluded, as were those with concurrent chronic systemic disorders.
Methods

EQUIPMENT
The system for recording nocturnal cough has been described previously.3 Essentially it consisted of a directional microphone placed near the child's bed connected to a UHER 4200 tape recorder with a voice activated switch. An acoustic delay ensured that the activating noise was recorded at operating speed by the tape recorder. Ten seconds after cessation ofcoughing the tape recorder stopped and the time of the episode was recorded on a second channel. The switch threshold was adjusted individually for each child before monitoring. The tape was analysed aurally to exclude extraneous noises and by a specially designed computer program to give the number of 10 second coughing episodes. As the cough counts have a skewed distribution, statistical comparisons were made using loge cough counts.
Overnight arterial oxygen saturation (Sao2) and pulse rate (averaged over three seconds) were recorded at one minute intervals using a Biox 3700 pulse oximeter attached to a Squirrel data logger (SQ32-3V/IL/3D, Grant Instruments Cambridge Ltd). The finger probe was firmly attached to the child with tape. The overnight data were then edited to exclude any episodes of poor probe connection and the mean overnight saturation calculated.
Each child was given a Wright mini peak flow meter to use at home. Other lung function tests were performed in the respiratory laboratory. Lung volumes and airway resistance were measured in a whole body plethysmograph (Jaeger Ltd) and expiratory flow rates by an electronic spirometer (Gould). Measurements were made before and after inhalation of bronchodilator and all results were converted to percentage predicted for heigh-t using standard published data.
TRIAL DESIGN
The trial consisted of one week run-in period followed by a double blind crossover with one week each of CRS 4 mg (Volmax, Glaxo UK) or placebo twice daily. During the run-in period placebo tablets were taken and the child asked to complete a standard diary card (with grades 0-3 for severity of symptoms of wheeze, day and night cough, exercise tolerance, and nasal symptoms) and twice daily peak flow recordings (7-8 am and 7-10 pm) using the Wright mini peak flow meter. During the week the child attended the lung function laboratory for assessment of lung function. On days 6 and 7 of the run-in week, the family were visited at home and overnight recordings of cough and Sao2 were made. At the same time the diary card was checked for completeness and inquiries made about compliance with medication and ability to swallow the tablets whole. If the child had completed the diary card, had taken the placebo satisfactorily, and had recorded at least 20 coughing episodes over the two nights, he/she was entered into the crossover phase.
Diary card requirements, peak flow, and overnight monitoring (cough, Sao2, and heart rate) in the second and third weeks were the same as for the run-in week; during this period each child was randomised to receive either CRS or placebo first. Deterioration in the control of asthma resulting in the prescription of oral steroids or admission to hospital was regarded as a treatment failure and the child withdrawn from the study. The Leicester Health Authority ethical committee approved the study and informed consent was given by parents before enrolment.
SAMPLE SIZE
The main outcome indicator of the trial was change in night cough. As the number of coughing episodes was not normally distributed it was expressed as loge cough. Using the SD of loge cough values from previous studies in similar children of 0-72 (unpublished observations), nine children would be needed to show a 50% reduction and 15 children to show a 45% reduction in number of coughing episodes, assuming a power for the study of 80%.
Results
Sixteen of the original 27 children completed the study. The 11 failures were excluded at the end of the run-in period. Six children did not meet the entry criteria of >20 coughing episodes over two nights, and five did not fill in the diary cards satisfactorily. None was withdrawn on medical grounds. Table 1 gives details of the children who completed the study. All were being treated with short acting inhaled 12 agonists and 13 were also receiving inhaled steroid medication. Lung function tests reflect the range of daytime Seven children (44%) received CRS first and there was no significant order effect for any of the variables measured. There was no significant improvement in loge cough with CRS (figure). In absolute numbers there was an increase in median cough counts on CRS from 12 0 to 14-5. The loge cough scores were almost identical (table 2), with confidence intervals for the difference equivalent to -2-0 to t 1-9 coughing episodes per night. The diary card cough score showed a deterioration of night cough on CRS (>0 05). There was also a deterioration of nasal symptoms on CRS. Sao2 saturation was not affected (mean=95-8% on both CRS and placebo). Mean peak flow (evening and morning) improved during the treatment week, the increase in morning peak flow on CRS being greatest (p=007). Mean peak flow variability overnight on CRS was not significantly reduced. The overnight pulse rate was significantly raised on CRS (mean=88 beats/minute compared with 76 beats/minute on placebo, p<0003). On examining the individual paired results, all the children had a higher pulse rate while on CRS.
Loge cough correlated with parental scoring of night cough (r=0-588, p<002) during the CRS week but not on placebo. Likewise, there Effect ofcontrolled release salbutamol on nocturnal cough in asthma 6 These studies were performed on adult patients with asthma or chronic bronchitis and neither included a placebo group. An unreviewed report of a similar trial in children showed no advantage of CRS over theophylline except that there was a small improvement in the morning and evening peak flow.7 Adverse effects were more cQmmon with theophylline. In our study there were no reported adverse events or withdrawals related to medication.
One further unreviewed report in children showed a significant improvement in morning and evening peak flow (16-3% and 21-5% respectively) on CRS but was not placebo controlled.8 Our study showed mean morning and evening peak flow to be higher on CRS. The Adverse reactions were relatively few. One child developed a fever and a swollen knee 16 days after the vaccination. Mild problems at the injection site, usually pain in the first three days, were experienced by 13% of children. Four percent developed a rash confined to the injection site and a further 4% had a varicelliform rash, which was usually mild, occurring at about 14 to 25 days after injection. Viral culture was attempted in 32 cases of post vaccination varicelliform rash and varicella zoster virus was isolated from 11. Nine of these isolates were typed by restriction endonuclease analysis and eight were shown to be wild virus and not the vaccine strain. Which just goes to show, you can't assume nut'n. Less than 1% of vaccinees had a fever of more than 38-9°C within three days and the incidence of fever in the six weeks after vaccination was no greater than might be expected in normal children.
Ninety six percent of vaccinees showed seroconversion at six weeks and all the non-responders given a second dose showed seroconversion after that. Antibodies persisted at one year in almost all cases. The vaccine showed an 86% efficacy in preventing chickenpox in household contacts in the first year after vaccination and when the disease occurred it was usually mild, the mean number of lesions being 32 compared with about 500 in natural chickenpox. Two mild cases of shingles have been reported in earlier trials of varicella vaccine but the incidence of shingles after vaccination seems to be no higher than after natural infection. Data from previous trials indicate that humoral immunity persists for at least four years. It will be necessary to continue to collect data on the persistence of immunity and the possible need for revaccination but the prospects for control of disease due to varicella zoster virus look good.
Next on the list must surely be respiratory syncytial virus. And then what shall we do in the winter time? Now Jonah, be quiet. What do you mean 'When we got rid of smallpox we got AIDS. When we get rid of chickenpox. . .?' Now that's no way to think, is it?
